Milford, MA (PRWEB) April 02, 2012
Avecia Biotechnology Inc., a leader in therapeutic nucleic acid manufacturing and development services, announces that effective April 1, 2012, they have changed their name to NITTO DENKO Avecia Inc.
This change is in alignment with the company’s acquisition in February 2011 by Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. There is no change in company management or location; Avecia continues to operate its oligonucleotide manufacturing and development facility in Milford, MA.
For further brand integration, Avecia incorporated the colors of Nitto Denko into its logo. A redesigned website, http://www.avecia.com, was launched to promote Avecia’s products and services, and its status as a Nitto Denko company.
Avecia remains committed to meeting the current and future needs of the oligonucleotide therapeutics market, and providing exceptional service to its customers.
[ABOUT NITTO DENKO Avecia Inc.]
NITTO DENKO Avecia Inc. is a drug development and manufacturing service company located in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. Avecia is a recognized leader in process development, manufacturing and related services for DNA and RNA-based therapeutics. All services are offered, from pre-clinical testing to post-commercial launch of innovative oligonucleotide-based therapeutics.